TY - JOUR
T1 - Tetrahydroquinoxalines induce a lethal evisceration phenotype in Haemonchus contortus in vitro
AU - Jiao, Yaqing
AU - Preston, Sarah
AU - Garcia-Bustos, Jose F.
AU - Baell, Jonathan B.
AU - Ventura, Sabatino
AU - Le, Thuy
AU - McNamara, Nicole
AU - Nguyen, Nghi
AU - Botteon, Antony
AU - Skinner, Cameron
AU - Danne, Jill
AU - Ellis, Sarah
AU - Koehler, Anson V.
AU - Wang, Tao
AU - Chang, Bill C.H.
AU - Hofmann, Andreas
AU - Jabbar, Abdul
AU - Gasser, Robin B.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - In the present study, the anthelmintic activity of a human tyrosine kinase inhibitor, AG-1295, and 14 related tetrahydroquinoxaline analogues against Haemonchus contortus was explored. These compounds were screened against parasitic larvae - exsheathed third-stage (xL3) and fourth-stage (L4) - using a whole-organism screening assay. All compounds were shown to have inhibitory effects on larval motility, development and growth, and induced evisceration through the excretory pore in xL3s. The estimated IC50 values ranged from 3.5 to 52.0 μM for inhibition of larval motility or development. Cytotoxicity IC50 against human MCF10A cells was generally higher than 50 μM. Microscopic studies revealed that this eviscerated (Evi) phenotype occurs rapidly (<20 min) and relates to a protrusion of internal tissues and organs (evisceration) through the excretory pore in xL3s; severe pathological damage in L4s as well as a suppression of larval growth in both stages were also observed. Using a relatively low concentration (12.5 μM) of compound m10, it was established that the inhibitor has to be present for a relatively short time (between 30 h and 42 h) during in vitro development from xL3 to L4, to induce the Evi phenotype. Increasing external osmotic pressure prevented evisceration and moulting, and xL3s remained unaffected by the test compound. These results point to a mode of action involving a dysregulation of morphogenetic processes during a critical time-frame, in agreement with the expected behaviour of a tyrosine kinase inhibitor, and suggest potential for development of this compound class as nematocidal drugs.
AB - In the present study, the anthelmintic activity of a human tyrosine kinase inhibitor, AG-1295, and 14 related tetrahydroquinoxaline analogues against Haemonchus contortus was explored. These compounds were screened against parasitic larvae - exsheathed third-stage (xL3) and fourth-stage (L4) - using a whole-organism screening assay. All compounds were shown to have inhibitory effects on larval motility, development and growth, and induced evisceration through the excretory pore in xL3s. The estimated IC50 values ranged from 3.5 to 52.0 μM for inhibition of larval motility or development. Cytotoxicity IC50 against human MCF10A cells was generally higher than 50 μM. Microscopic studies revealed that this eviscerated (Evi) phenotype occurs rapidly (<20 min) and relates to a protrusion of internal tissues and organs (evisceration) through the excretory pore in xL3s; severe pathological damage in L4s as well as a suppression of larval growth in both stages were also observed. Using a relatively low concentration (12.5 μM) of compound m10, it was established that the inhibitor has to be present for a relatively short time (between 30 h and 42 h) during in vitro development from xL3 to L4, to induce the Evi phenotype. Increasing external osmotic pressure prevented evisceration and moulting, and xL3s remained unaffected by the test compound. These results point to a mode of action involving a dysregulation of morphogenetic processes during a critical time-frame, in agreement with the expected behaviour of a tyrosine kinase inhibitor, and suggest potential for development of this compound class as nematocidal drugs.
KW - Anthelmintic
KW - Evisceration (Evi) phenotype
KW - Haemonchus
KW - Moulting
KW - Quinoxalines
KW - Whole-organism screening
UR - http://www.scopus.com/inward/record.url?scp=85060444961&partnerID=8YFLogxK
U2 - 10.1016/j.ijpddr.2018.12.007
DO - 10.1016/j.ijpddr.2018.12.007
M3 - Article
AN - SCOPUS:85060444961
SN - 2211-3207
VL - 9
SP - 59
EP - 71
JO - International Journal for Parasitology: Drugs and Drug Resistance
JF - International Journal for Parasitology: Drugs and Drug Resistance
ER -